4:08 AM
 | 
Jan 03, 2018
 |  BC Extra  |  Company News

Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a peptide...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >